Acute Effects of a Urate-lowering Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects
Key facts
- Who runs it
- Örebro University, Sweden
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 8 people, planned
- Started
- 9 Apr 2026
- Expected to end
- Jun 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- BEO001 Probiotic
- BEO001 Probiotic + Beta-Glucan
- Placebo
- Record updated
- 20 October 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Signed informed consent
- Age 18-60 years
- BMI 18.5 - 29.9 kg/m²
- Willing to avoid probiotics, fermented foods, and maintain stable diet/lifestyle for the study duration
Who cannot take part
- Regular use of NSAIDs, antibiotics, steroids, immunomodulators
- Use of recreational drugs, tobacco, or nicotine
- Use of probiotics or antibiotics within 4 weeks prior
- Chronic GI, inflammatory, metabolic (including renal), or significant psychiatric disease
- Acute infection/allergy within 2 weeks
- Known allergy to local anesthetics or sedatives for gastroscopy
- Bleeding disorder or use of anticoagulants
- Any condition deemed by investigator to compromise safety or data integrity
- Alcohol >9 units/week
- Pregnancy, breastfeeding, or planning pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a pilot study investigating how a novel probiotic supplement (BEO001), with and without a dietary fiber (beta-glucan), affects the lining of the small intestine in healthy people. The main goal is to see if a single dose of the probiotic changes gene activity (transcriptomics) and sugar molecule patterns (glycomics) in the gut. Eight participants will take three different treatments (placebo, probiotic alone, probiotic with fiber) in a random order, with at least 10 days between each. A gastroscopy to collect small intestinal tissue samples (biopsies) is performed the morning after each treatment. Blood and breath samples are also collected at these visits to explore effects on metabolism and inflammation. To understand how different sampling methods compare, participants collect stool samples and simple rectal swabs at home before any treatment. Researchers analyze the sugar molecules and bacteria in these samples, then compare them to each other and to the gut tissue samples collected after treatment. This helps determine if easier-to-collect samples can provide similar information to gut biopsies. The study also aims to combine all data (including genetics and diet) to identify key targets for future research and to attempt to grow 'mini-gut' organoids from the biopsies. The results will help design larger future studies in people with high uric acid levels.
The 3 groups in the trial
- Probiotic (BEO001)Existing treatment, for comparison
Participants receive the BEO001 probiotic powder, which contains two probiotic strains
Treatment: BEO001 Probiotic
- Synbiotic (BEO001 + Beta-Glucan)Existing treatment, for comparison
Participants receive the BEO001 probiotic powder plus beta-glucan fiber powder.
Treatment: BEO001 Probiotic + Beta-Glucan
- PlaceboPlacebo, for comparison
Participants receive placebo powder.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Acute Effects of a Urate-lowering Probiotic Food Supplement/Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects
- Record updated
- 20 October 2026